Johnson & Johnson - Top 10 pharma layoffs of 2011

Company: Johnson & Johnson ($JNJ)
Based: New Brunswick, NJ
Job cuts announced: up to 1,000
Date revealed: June 16
Theme: Cardiac stent sayonara

The scoop: Johnson & Johnson Cypher stents claimed a 51% share of the market as recently as 2006. In 2010, that market dominance all but evaporated, plunging to a humbling 16% as competitors cropped up with cutting-edge alternatives and cardiac stent placement declined. J&J took action, announcing in June that its Cordis unit would stop making the Cypher and Cypher Select drug-coated stents by the end of 2011. The move eliminates as many as 1,000 jobs and shuts down two factories, the company said.

J&J took a $500 million to $600 million charge against earnings, but the cuts had to be made, according to articles in Reuters, The New York Times and others, which noted that the move frees up J&J/Cordis to focus more on diagnostics and noncardiac stents.

Johnson & Johnson - Top 10 pharma layoffs of 2011

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.